-
Evolution of Personalized Cancer Care With Molecular Profiling
21 Jan 2025 23:54 GMT
… Tarceva) and gefitinib (Iressa) have improved survival … , such as personalized cancer vaccines, where AI is … influencing clinical trials and immunotherapy approaches in cancer treatment.
“ … 47;NEJMoa052122
Gleevec FDA approval history. Drugs. Updated February …
-
Advancement of First-Line Treatments on EGFR-Mutated NSCLC
18 Jan 2025 00:27 GMT
… institutions, CancerNetwork hosted a panel discussion on treatment options … Cleveland Medical Center; Giselle Dutcher, MD,medical oncologist … . Then the osimertinib trial looking at atypical [ … standard of care gefitinib [Iressa] or erlotinib [Tarceva]. …
-
University of Chicago Thought Process on First-line Treatment in EGFR NSCLC
18 Jan 2025 00:27 GMT
… ) trials.1-3 The panelists focused on how each treatment regimen … MD, associate professor of medicine. Additional panelists included James Wallace … trial was to look at arm A vs arm B. The FDA … Oncology. Non-small cell lung cancer, version 11.24. Accessed …
-
US FDA accepts and grants priority review status to AstraZeneca & Daiichi Sankyo's BLA for Dato─DXd for patients with previously treated advanced EGFR─mutated NSCLC
14 Jan 2025 08:38 GMT
… Drug Administration (FDA) grants Priority Review to applications for medicines … treatment for patients with NSCLC in seven phase III trials … III trial evaluating … cancer medicines and the next wave of innovations, including Tagrisso (osimertinib) and Iressa …
-
AstraZeneca's Imfinzi receives US FDA approval to treat patients with limited─stage small cell lung cancer
06 Dec 2024 04:06 GMT
… Food and Drug Administration (FDA) after securing … trials to identify new treatment options for this type of cancer … phase III trial evaluating Imfinzi monotherapy … cancer medicines and the next wave of innovations, including Tagrisso (osimertinib) and Iressa …
-
Afatinib/Osimertinib Treatment Combinations in EGFR-Mutated Advanced NSCLC
31 Dec 2024 13:28 GMT
… institutions, CancerNetwork hosted a panel discussion on treatment options … Cleveland Medical Center; Giselle Dutcher, MD,medical oncologist … . Then the osimertinib trial looking at atypical [ … standard of care gefitinib [Iressa] or erlotinib [Tarceva]. …
-
Nonmelanoma Skin Cancer Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight
17 Dec 2024 13:16 GMT
… Cancer epidemiology trends @ Nonmelanoma Skin Cancer Epidemiology Forecast
Nonmelanoma Skin Cancer Drugs … the treatment market, visit @ Nonmelanoma Skin Cancer Clinical Trials … Cancer Current Treatment and Medical Practices
10. Nonmelanoma Skin Cancer …
-
US FDA grants breakthrough therapy designation to datopotamab deruxtecan for patients with previously treated advanced EGFR-mutated NSCLC
10 Dec 2024 05:11 GMT
… FDA underscores the significant unmet need for new treatments … the trial.
The primary trial endpoint … trials in lung cancer and five phase III trials in breast cancer … cancer medicines and the next wave of innovations, including Tagrisso (osimertinib) and Iressa …
-
AstraZeneca, Daiichi Sankyo seek US FDA's accelerated approval for datopotamab deruxtecan to treat advanced EGFR─mutated NSCLC
13 Nov 2024 07:09 GMT
… and Drug Administration (FDA).
The … treatment is available. The dose escalation portion of the trial … trials in lung cancer and five phase III trials in breast cancer … cancer medicines and the next wave of innovations, including Tagrisso (osimertinib) and Iressa …
-
Bumrungrad Health Briefs #42: Targeted Therapy: A Precision Approach to Cancer Treatment
25 Oct 2024 08:51 GMT
… A Precision Approach to Cancer Treatment
Cancer treatment is advancing rapidly through … cancer cells, sparing normal cells.
This form of precision medicine … targeted drugs like erlotinib (Tarceva) or gefitinib (Iressa).
Colorectal Cancer: Cancers with …
About
© 1995-2025